1. Investigating the effect of enhanced cleaning and disinfection of shared medical equipment on health-care-associated infections in Australia (CLEEN): a stepped-wedge, cluster randomised, controlled trial.
- Author
-
Browne K, White NM, Russo PL, Cheng AC, Stewardson AJ, Matterson G, Tehan PE, Graham K, Amin M, Northcote M, Kiernan M, King J, Brain D, and Mitchell BG
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Adult, New South Wales epidemiology, Infection Control methods, Housekeeping, Hospital methods, Australia epidemiology, Disinfection methods, Cross Infection prevention & control, Cross Infection epidemiology
- Abstract
Background: There is a paucity of high-quality evidence based on clinical endpoints for routine cleaning of shared medical equipment. We assessed the effect of enhanced cleaning and disinfection of shared medical equipment on health-care-associated infections (HAIs) in hospitalised patients., Methods: We conducted a stepped-wedge, cluster randomised, controlled trial in ten wards of a single hospital located on the central coast of New South Wales, Australia. Hospitals were eligible for inclusion if they were classified as public acute group A according to the Australian Institute of Health and Welfare, were located in New South Wales, had an intensive care unit, had a minimum of ten wards, and provided care for patients aged 18 years or older. Each cluster consisted of two randomly allocated wards (by use of simple randomisation), with a new cluster beginning the intervention every 6 weeks. Wards were informed of their allocation 2 weeks before commencement of intervention exposure, and the researcher collecting primary outcome data and audit data was masked to treatment sequence allocation. In the control phase, there was no change to environmental cleaning practices. In the intervention phase, a multimodal cleaning bundle included an additional 3 h per weekday for the dedicated cleaning and disinfection of shared medical equipment by 21 dedicated cleaning staff, with ongoing education, audit, and feedback. The primary outcome was the number of confirmed cases of HAI, as assessed by a fortnightly point prevalence survey and measured in all patients admitted to the wards during the study period. The completed trial is registered with Australia New Zealand Clinical Trials Registry (ACTRN12622001143718)., Findings: The hospital was recruited on July 31, 2022, and the study was conducted between March 20 and Nov 24, 2023. We assessed 220 hospitals for eligibility, of which five were invited to participate, and the first hospital to formally respond was enrolled. 5002 patients were included in the study (2524 [50·5%] women and 2478 [49·5%] men). In unadjusted results, 433 confirmed HAI cases occurred in 2497 patients (17·3%, 95% CI 15·9 to 18·8) in the control phase and 301 confirmed HAI cases occurred in 2508 patients (12·0%, 10·7 to 13·3) in the intervention phase. In adjusted results, there was a relative reduction of -34·5% (-50·3 to -17·5) in HAIs following the intervention (odds ratio 0·62, 95% CI 0·45 to 0·80; p=0·0006), corresponding to an absolute reduction equal to -5·2% (-8·2 to -2·3). No adverse effects were reported., Interpretation: Improving the cleaning and disinfection of shared medical equipment significantly reduced HAIs, underscoring the crucial role of cleaning in improving patient outcomes. Findings emphasise the need for dedicated approaches for cleaning shared equipment., Funding: National Health and Medical Research Council., Competing Interests: Declaration of interests BGM declares grants from GAMA Healthcare paid to their institution; consulting fees from ICS Service Solutions paid to their institution; honoraria for their role as Editor-in-Chief of Infection, Disease and Health and from the Australasian College for Infection Prevention and Control; non-financial leadership roles within the Australian Government (Commonwealth) National Health and Medical Research Council, the National Infection Control Guidelines Committee, and the Australian Infection Control Guidelines expert group; and receipt of Clinell wipes from GAMA Healthcare provided to their institution. ACC declares grant funding from the National Health and Medical Research Council and the Australian Government Department of Health; consulting fees from the Therapeutic Goods Administration; participation on advisory boards for non-pharmaceutical trials (on the topic of prevention of infections in haematological malignancy); a past role as President of the Australasian Society for Infectious Diseases; and other non-financial interests in the Australian Infection Control Guidelines expert group. PET declares grants from the Urgo Foundation, the Australian Podiatry Association, the Department of Health and Aged Care, Wounds Australia, and the Australian Podiatry Education Research Foundation. MK declares former part-time consultant contracts from GAMA Healthcare and support for attending conferences from GAMA Healthcare, including travel expenses and accommodation. MK was an invited speaker at the conferences and did not receive any honoraria amount. AJS, DB, GM, JK, KB, KG, MA, MN, NMW, and PLR declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF